Trial Profile

Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
Sponsors Pharmacyclics

08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 16).
14 Jun 2015 Results (from this study and PCYC-1103-CA) presented at the 20th Congress of the European Haematology Association (n = 4).
10 Dec 2013 Results from a long-term analysis (extension study) presented at the 55th Annual Meeting of the American Society of Hematology (ASH-2013; abstract #4163), according to a Pharmacyclics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com